Amgen (AMGN) Misses Q2 EPS by 1c; updates guidance
Tweet
Share
E-mail_58cbc46cd3c33.jpg)
Get Alerts AMGN Hot Sheet
Price: $443.84 +1.03%
Financial Fact:
Selling, general and administrative: 1.24B
Today's EPS Names:
XYF, SQZB, RENO, More
Financial Fact:
Selling, general and administrative: 1.24B
Today's EPS Names:
XYF, SQZB, RENO, More
Join SI Premium – FREE
Amgen (NASDAQ: AMGN) reported Q2 EPS of $4.97, $0.01 worse than the analyst estimate of $4.98. Revenue for the quarter came in at $8.39 billion versus the consensus estimate of $8.35 billion.
GUIDANCE:
Amgen sees FY2024 EPS of $19.10-$20.10, versus the consensus of $17.87. Amgen sees FY2024 revenue of $32.8-33.8 billion, versus the consensus of $30.3 billion.
For earnings history and earnings-related data on Amgen (AMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aggreko files for proposed IPO
- Co-Diagnostics (CODX) files for 3.4M share offering by selling stockholders
- Tetra Tech EC pays $57M to settle false soil test claims
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
